Please note that following on from information provided to NICE by the company in December 2008, the appraisal of Ixabepilone for locally advanced or metastatic breast cancer [ID377] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 377 |
| Referral date | 01 December 2007 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | 02 October 2008 |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Sarita Tamber |
| Executive Lead: | Gillian Leng |
| Project manager: | Laura Malone |
| Technical Lead: | Helen Tucker |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in December 2008, the appraisal of Ixabepilone for locally advanced or metastatic breast cancer [ID377] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 9 December 2008 | The manufacturer recently received a negative CHMP opinion for Ixabepilone for locally advanced or metastatic breast cancer. Consequently this appraisal will be suspended until we receive an update from the manufacturer on the status of regulatory approval. |
For further information on our processes and methods, please see our CHTE processes and methods manual